

Resource Summary Report

Generated by [FDI Lab - SciCrunch.org](#) on May 17, 2025

Hepa 1-6

RRID:CVCL_0327

Type: Cell Line

Proper Citation

(RCB Cat# RCB1638, RRID:CVCL_0327)

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_0327

Proper Citation: (RCB Cat# RCB1638, RRID:CVCL_0327)

Sex: Female

Defining Citation: [PMID:11004682](#), [PMID:12606785](#), [PMID:25193168](#), [PMID:26280412](#), [PMID:28152020](#), [PMID:31220119](#)

Comments: Omics: Transcriptome analysis by microarray., Omics: Deep proteome analysis., Omics: Deep phosphoproteome analysis., Omics: Array-based CGH., Characteristics: Secretes several liver products including albumin, alpha-fetoprotein, alpha 1-antitrypsin and amylase (ECACC=92110305).

Category: Cancer cell line

Name: Hepa 1-6

Synonyms: HEPA 1-6, Hepa-1-6, Hepa1-6

Cross References: BTO:BTO_0002895, CLO:CLO_0003711, CLO:CLO_0050769, EFO:EFO_0022833, MCCL:MCC:0000223, CLDB:cl1658, CLDB:cl1659, CLDB:cl5199, AddexBio:C0015005/4999, ATCC:CRL-1830, BCRC:60051, BioSample:SAMN11397636, CCRID:1101MOU-PUMC000106, CCRID:3101MOUSCSP512, CCRID:3101MOUTCM39, CCRID:4201MOU-CCTCC00313, CCRID:6101MOU-CERC000105, CCTCC:GDC0313, CLS:400474, DSMZ:ACC-175, DSMZCellDive:ACC-175, ECACC:92110305, GEO:GSM1374085, GEO:GSM1374086, GEO:GSM1374087, GEO:GSM1374088, GEO:GSM1374089, GEO:GSM1374090, IZSLER:BS TCL 157, Lonza:830, NCBI_Iran:C517, PRIDE:PXD001792, RCB:RCB1638, Ubigen:YC-A005, Wikidata:Q54882820

ID: CVCL_0327

Vendor: RCB

Catalog Number: RCB1638

Record Creation Time: 20250131T200407+0000

Record Last Update: 20250131T201627+0000

Ratings and Alerts

No rating or validation information has been found for Hepa 1-6.

No alerts have been found for Hepa 1-6.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 713 mentions in open access literature.

Listed below are recent publications. The full list is available at [FDI Lab - SciCrunch.org](#).

Yoshida Y, et al. (2025) Targeting macrophage circadian rhythms with microcurrent stimulation to activate cancer immunity through phagocytic defense. *Theranostics*, 15(2), 340.

Wei R, et al. (2025) Improved split prime editors enable efficient in vivo genome editing. *Cell reports*, 44(1), 115144.

Mei Y, et al. (2024) IL-37 dampens immunosuppressive functions of MDSCs via metabolic reprogramming in the tumor microenvironment. *Cell reports*, 43(3), 113835.

Yoshida Y, et al. (2024) Circadian rhythms in CYP2A5 expression underlie the time-dependent effect of tegafur on breast cancer. *Biochemical and biophysical research communications*, 708, 149813.

Gan WL, et al. (2024) Hepatocyte-macrophage crosstalk via the PGRN-EGFR axis modulates ADAR1-mediated immunity in the liver. *Cell reports*, 43(7), 114400.

Song M, et al. (2024) DNA of Neutrophil Extracellular Traps Binds TMCO6 to Impair CD8+ T-cell Immunity in Hepatocellular Carcinoma. *Cancer research*, 84(10), 1613.

- Ning J, et al. (2024) Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation. *Cell reports. Medicine*, 5(5), 101505.
- Mu M, et al. (2024) Targeting Ferroptosis-Elicited Inflammation Suppresses Hepatocellular Carcinoma Metastasis and Enhances Sorafenib Efficacy. *Cancer research*, 84(6), 841.
- Liebold I, et al. (2024) Apoptotic cell identity induces distinct functional responses to IL-4 in efferocytic macrophages. *Science (New York, N.Y.)*, 384(6691), eabo7027.
- Tang H, et al. (2024) Chemically engineered mTOR-nanoparticle blockers enhance antitumour efficacy. *EBioMedicine*, 103, 105099.
- Qiu J, et al. (2024) Hypoxia-responsive lncRNA MIR155HG promotes PD-L1 expression in hepatocellular carcinoma cells by enhancing HIF-1 α mRNA stability. *International immunopharmacology*, 136, 112415.
- Scholtes C, et al. (2024) Identification of a chromatin-bound ERR α interactome network in mouse liver. *Molecular metabolism*, 83, 101925.
- Qiu L, et al. (2024) TLR3 activation enhances abscopal effect of radiotherapy in HCC by promoting tumor ferroptosis. *EMBO molecular medicine*, 16(5), 1193.
- Yang Y, et al. (2024) Dietary vitamin B3 supplementation induces the antitumor immunity against liver cancer via biased GPR109A signaling in myeloid cell. *Cell reports. Medicine*, 5(9), 101718.
- Bugide S, et al. (2024) ALK inhibitors suppress HCC and synergize with anti-PD-1 therapy and ABT-263 in preclinical models. *iScience*, 27(5), 109800.
- Chen Z, et al. (2024) SIGLEC15, negatively correlated with PD-L1 in HCC, could induce CD8 $^{+}$ T cell apoptosis to promote immune evasion. *Oncoimmunology*, 13(1), 2376264.
- Gonzalez-Sandoval A, et al. (2023) The AAV capsid can influence the epigenetic marking of rAAV delivered episomal genomes in a species dependent manner. *Nature communications*, 14(1), 2448.
- Liang X, et al. (2023) Abrine, an IDO1 inhibitor, suppresses the immune escape and enhances the immunotherapy of anti-PD-1 antibody in hepatocellular carcinoma. *Frontiers in immunology*, 14, 1185985.
- You J, et al. (2023) Lentinan induces apoptosis of mouse hepatocellular carcinoma cells through the EGR1/PTEN/AKT signaling axis. *Oncology reports*, 50(1).
- Guo Q, et al. (2023) A novel NEDD4L-TXNIP-CHOP axis in the pathogenesis of nonalcoholic steatohepatitis. *Theranostics*, 13(7), 2210.